Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer. Soleimani Dodaran M, Borgoni S, Sofyali E, Verschure PJ, et al. BMC Cancer 2020;20:676.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Soleimani Dodaran M, Borgoni S, Sofyali E, Verschure PJ, et al. Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer. BMC Cancer 2020;20:676.
PMID: 32684154